End-of-day quote
Korea S.E.
06:00:00 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
4,210
KRW
|
+0.24%
|
|
-0.47%
|
+0.48%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,172,660
|
969,689
|
858,749
|
548,450
|
446,056
|
293,942
|
Enterprise Value (EV)
1 |
1,186,544
|
989,663
|
877,311
|
567,943
|
473,383
|
324,224
|
P/E ratio
|
-78
x
|
-45.4
x
|
-305
x
|
-123
x
|
-68.5
x
|
-73.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
33.5
x
|
27.3
x
|
23.1
x
|
15.3
x
|
11.2
x
|
6.89
x
|
EV / Revenue
|
33.9
x
|
27.9
x
|
23.6
x
|
15.8
x
|
11.9
x
|
7.6
x
|
EV / EBITDA
|
-447
x
|
-628
x
|
561
x
|
-332
x
|
21,189
x
|
-118
x
|
EV / FCF
|
-180
x
|
-159
x
|
-559
x
|
-197
x
|
-147
x
|
-162
x
|
FCF Yield
|
-0.56%
|
-0.63%
|
-0.18%
|
-0.51%
|
-0.68%
|
-0.62%
|
Price to Book
|
12
x
|
13.2
x
|
11.3
x
|
8.25
x
|
7.34
x
|
5.22
x
|
Nbr of stocks (in thousands)
|
69,941
|
69,989
|
70,276
|
70,276
|
70,239
|
70,153
|
Reference price
2 |
16,766
|
13,855
|
12,220
|
7,804
|
6,351
|
4,190
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/16/22
|
3/15/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
34,994
|
35,490
|
37,160
|
35,847
|
39,801
|
42,647
|
EBITDA
1 |
-2,653
|
-1,576
|
1,565
|
-1,708
|
22.34
|
-2,744
|
EBIT
1 |
-6,214
|
-5,434
|
-2,175
|
-5,291
|
-3,804
|
-6,273
|
Operating Margin
|
-17.76%
|
-15.31%
|
-5.85%
|
-14.76%
|
-9.56%
|
-14.71%
|
Earnings before Tax (EBT)
1 |
-19,059
|
-13,851
|
-3,957
|
-5,934
|
-7,480
|
-5,739
|
Net income
1 |
-14,303
|
-21,363
|
-2,816
|
-4,459
|
-6,514
|
-3,979
|
Net margin
|
-40.87%
|
-60.2%
|
-7.58%
|
-12.44%
|
-16.37%
|
-9.33%
|
EPS
2 |
-214.9
|
-305.5
|
-40.10
|
-63.64
|
-92.73
|
-57.00
|
Free Cash Flow
1 |
-6,609
|
-6,207
|
-1,569
|
-2,886
|
-3,218
|
-2,004
|
FCF margin
|
-18.89%
|
-17.49%
|
-4.22%
|
-8.05%
|
-8.09%
|
-4.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/16/22
|
3/15/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
13,884
|
19,975
|
18,563
|
19,493
|
27,327
|
30,282
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-5.233
x
|
-12.67
x
|
11.86
x
|
-11.41
x
|
1,223
x
|
-11.04
x
|
Free Cash Flow
1 |
-6,609
|
-6,207
|
-1,569
|
-2,886
|
-3,218
|
-2,004
|
ROE (net income / shareholders' equity)
|
-15.1%
|
-26.7%
|
-5.13%
|
-7.89%
|
-10.8%
|
-9.41%
|
ROA (Net income/ Total Assets)
|
-2.69%
|
-2.56%
|
-1.1%
|
-2.79%
|
-2.09%
|
-3.4%
|
Assets
1 |
532,531
|
835,120
|
256,407
|
159,925
|
311,010
|
116,891
|
Book Value Per Share
2 |
1,402
|
1,047
|
1,085
|
946.0
|
865.0
|
803.0
|
Cash Flow per Share
2 |
288.0
|
270.0
|
214.0
|
171.0
|
154.0
|
211.0
|
Capex
1 |
5,434
|
5,740
|
1,656
|
813
|
848
|
637
|
Capex / Sales
|
15.53%
|
16.17%
|
4.46%
|
2.27%
|
2.13%
|
1.49%
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/16/22
|
3/15/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| +0.48% | 214M | | -9.29% | 81.7B | | -7.35% | 6.82B | | +33.75% | 3.96B | | +0.14% | 3.29B | | +19.93% | 1.76B | | -4.00% | 1.27B | | -37.88% | 1.03B | | -42.33% | 963M | | -19.10% | 846M |
Veterinary Drugs
|